Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03259347 · ClinicalTrials.gov registry record · NA
Eating Disorders Programs: An Indicated Trial
A NA study, sponsored by Oregon Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 534
- Enrollment target
NCT03259347: Completed NA study, sponsored by Oregon Research Institute.
NCT03259347 is a NA study that has completed, run by Oregon Research Institute. The registered enrollment target is 534 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03259347, a NA study, has completed, sponsored by Oregon Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 534 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effectiveness of two body acceptance programs for women. Participants may experience reduction of eating pathology and prevention of future obesity and eating disorders; may derive a sense of altruism and contribution to furthering understanding of a public health problem.
Primary Outcome
Evaluate change (if any) by using the Eating Disorder Examination questionnaire at the 8 week and 6 month mark.
Interventions
- BEHAVIORAL Group-based Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 534 participants |
| Start Date | 2012-06-01 |
| Est. Completion | 2018-04-01 |
| Phase | NA |
What the finished NCT03259347 record still lists
NCT03259347 is an interventional study that assigns participants to a tested intervention. The registered 534 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 1 intervention - of which Group-based Therapy is the first listed.
NCT03259347 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03259347 about?
NCT03259347 is a clinical study titled "Eating Disorders Programs: An Indicated Trial". The purpose of this study is to assess the effectiveness of two body acceptance programs for women. Participants may experience reduction of eating pathology and prevention of future obesity and eating disorders; may derive a sense of altruism and contribution to furthering understanding of a public...
What is the current status of trial NCT03259347?
This trial is currently completed. It is a NA study. The enrollment target is 534 participants. The study started on 2012-06-01. Estimated completion is 2018-04-01.
What interventions are being tested in trial NCT03259347?
The interventions under investigation include: Group-based Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT03259347?
This trial is sponsored by Oregon Research Institute, which has 62 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03259347's enrollment target sits among peer trials
534 188th of 2000 higher than 1,813 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04910685 · 534 participants · Phase 2
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
- NCT06128551 · 534 participants · Phase 1
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- NCT05614739 · 535 participants · Phase 1
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
- NCT07091617 · 535 participants · NA
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI